专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0166099A3 USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS 审中-公开
标题翻译：喹诺酮衍生物作为血管生成抑制剂的使用
公开(公告)号：WO0166099A3
公开(公告)日：2002-03-21
申请号：PCT/GB0100863
申请日：2001-03-01
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , HENNEQUIN LAURENT FRANCOIS AND , CRAWLEY GRAHAM CHARLES , MCKERRECHER DARREN , PLE PATRICK , POYSER JEFFREY PHILIP , LAMBERT CHRISTINE MARIE PAUL
发明人： HENNEQUIN LAURENT FRANCOIS AND , CRAWLEY GRAHAM CHARLES , MCKERRECHER DARREN , PLE PATRICK , POYSER JEFFREY PHILIP , LAMBERT CHRISTINE MARIE PAUL
IPC分类号： C07D239/94 , A61K31/505 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61P3/10 , A61P9/00 , A61P9/10 , A61P13/12 , A61P15/00 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D487/04 , C07D495/04 , A61P37/00 , C07D521/00
CPC分类号： A61K31/519 , A61K31/517 , A61K31/5377
摘要： The invention concerns the use of a quinazoline derivative of Formula (I) wherein Q includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q -X - wherein X includes a direct bond and O and Q includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R and R is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.
摘要翻译：本发明涉及使用式（I）的喹唑啉衍生物，其中Q 1包括任选被诸如卤代，三氟甲基和氰基的基团取代的喹唑啉环，或下式的基团：Q 3 -X 其中X 1包括直接键，O和Q 3包括芳基，芳基 - （1-6C）烷基，杂环基和杂环基 - （1-6C）烷基; R 2和R 3各自为氢或（1-6C）烷基; Z包括O，S和NH; 和Q 2包括芳基和芳基 - （1-3C）烷基或其药学上可接受的盐在制备用于在温血中产生抗血管生成和/或血管通透性降低作用的药物中的用途动物如人类。

2. 发明申请

WO0194341A9 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS 审中-公开
标题翻译：用于治疗肿瘤的喹诺酮衍生物
公开(公告)号：WO0194341A9
公开(公告)日：2003-04-17
申请号：PCT/GB0102424
申请日：2001-06-01
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , HENNEQUIN LAURENT FRANCOIS AND , PLE PATRICK
发明人： HENNEQUIN LAURENT FRANCOIS AND , PLE PATRICK
IPC分类号： A61K20060101 , A61K31/505 , A61K31/517 , A61K31/5377 , A61K31/541 , A61P20060101 , A61P35/00 , C07D20060101 , C07D235/00 , C07D239/94 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D521/00 , C07D235/06
CPC分类号： C07D401/14 , C07D231/12 , C07D233/56 , C07D239/94 , C07D249/08 , C07D401/12 , C07D405/12 , C07D405/14
摘要： The invention concerns quinazoline derivatives of Formula (I) wherein each of Q , Z, m, R , R , R and Q have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.
摘要翻译：本发明涉及式（I）的喹唑啉衍生物，其中Q 1，Z，m，R 1，R 2，R 3和Q 2中的每一个具有在说明书中定义的任何含义 ; 其制备方法，含有它们的药物组合物及其在制备用作在实体瘤疾病的遏制和/或治疗中作为抗侵入剂的药物的用途。

3. 发明申请

WO0212227A3 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY 审中-公开
标题翻译：具有VEGF抑制活性的吲哚，亚胺和吲哚衍生物
公开(公告)号：WO0212227A3
公开(公告)日：2002-08-01
申请号：PCT/GB0103561
申请日：2001-08-08
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , HENNEQUIN LAURENT FRANCOIS AND
发明人： HENNEQUIN LAURENT FRANCOIS AND
IPC分类号： A61K31/50 , A61K31/502 , A61K31/5025 , A61K31/519 , A61P3/10 , A61P9/10 , A61P15/08 , A61P17/00 , A61P17/06 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07D401/14 , C07D495/04
CPC分类号： C07D401/14 , A61K31/502 , A61K31/5025 , C07D495/04
摘要： The invention relates to compounds of the formula (I): wherein: ring C is 9 or 10-membered bicyclic heteroaromatic group containing at least one nitrogen atom in the ring attached to Z and optionally containing a further 1-3 heteroatoms, selected independently from O, S and N, with the proviso that ring C is not a quinazoline, quinoline or cinnoline group; either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are -CH-; or G1, G2, G3, G4 and G5 are all -CH-; Z is -O-, NH-, -S-, CH2- or a direct bond, Z is linked to any one of G1, G2, G3 and G4; n is an integer from 0 to 5; any of the substituents R may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 2; R , R and R are as defined herein and salts thereof, which are useful for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
摘要翻译：本发明涉及式（I）的化合物：其中：环C是9或10元双环杂芳基，其在与Z连接的环中含有至少一个氮原子，并任选地含有另外1-3个杂原子，其独立地选自 O，S和N，条件是环C不是喹唑啉，喹啉或噌啉基; G1，G2，G3，G4和G5中的任一个是氮，而另外四个是-CH-; 或G1，G2，G3，G4和G5均为-CH-; Z是-O-，NH-，-S-，CH2-或直接键，Z连接到G1，G2，G3和G4中的任一个; n为0〜5的整数，任何取代基R 1可以连接在吲哚，氮杂吲哚或吲唑基团的任何游离碳原子上; m为0〜2的整数; R 1，R 1和R 2如本文所定义，及其盐，其可用于在温血动物中产生抗血管生成和/或血管通透性降低作用。式（I）化合物及其药学上可接受的盐抑制VEGF的作用，其在治疗许多疾病状态（包括癌症和类风湿性关节炎）中是有价值的。

4. 发明申请

WO03053960A3 QUINLINE DERIVATES AND THEIR USE AS MEK INHIBITORS 审中-公开
标题翻译： QUINLINE衍生物及其作为MEK抑制剂的用途
公开(公告)号：WO03053960A3
公开(公告)日：2003-09-12
申请号：PCT/GB0205518
申请日：2002-12-05
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , HENNEQUIN LAURENT FRANCOIS AND , GIBSON KEITH HOPKINSON , FOOTE KEVIN MICHAEL
发明人： HENNEQUIN LAURENT FRANCOIS AND , GIBSON KEITH HOPKINSON , FOOTE KEVIN MICHAEL
IPC分类号： A61P43/00 , C07D413/12 , A61K31/47
CPC分类号： C07D413/12
摘要： The invention concerns quinoline derivatives of Formula (I) wherein each of Z, m, R1, n and R3, X, Y and W have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-proliferative agent in the containment and/or treatment of solid tumour disease.
摘要翻译：本发明涉及式（I）的喹啉衍生物，其中Z，m，R 1，n和R 3，X，Y和W中的每一个具有上文在描述中定义的任何含义; 其制备方法，含有它们的药物组合物及其在制备用作在固体肿瘤疾病的遏制和/或治疗中作为抗增殖剂的药物的用途。

5. 发明申请

WO03040109A2 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS 审中-公开
标题翻译：喹诺酮衍生物作为抗菌剂
公开(公告)号：WO03040109A2
公开(公告)日：2003-05-15
申请号：PCT/GB0204932
申请日：2002-10-31
申请人： ASTRAZENECA AB , ASTRAZENECA UK LTD , HENNEQUIN LAURENT FRANCOIS AND , KETTLE JASON GRANT , PASS MARTIN , BRADBURY ROBERT HUGH
发明人： HENNEQUIN LAURENT FRANCOIS AND , KETTLE JASON GRANT , PASS MARTIN , BRADBURY ROBERT HUGH
IPC分类号： A61K31/517 , A61K31/5377 , A61P35/00 , A61P43/00 , C07D239/94 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D411/12 , C07D413/12 , C07D413/14 , C07D417/14 , A61K31/505 , C07D407/12
CPC分类号： C04B35/632 , C07D239/94 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： The invention concerns quinazoline derivatives of Formula (I); wherein each of Q , Q , Z, R , R , R , L and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
摘要翻译：本发明涉及式（I）的喹唑啉衍生物; 其中Q 1，Q 2，Z，R 1，R 2，R 3，L和m各自具有本说明书中定义的任何含义; 其制备方法，含有它们的药物组合物及其在制备用于预防或治疗对erbB受体酪氨酸激酶的抑制敏感的肿瘤的药物中的用途。

6. 发明申请

WO9707769A3 CHEMICAL COMPOUNDS 审中-公开
标题翻译：化学化合物
公开(公告)号：WO9707769A3
公开(公告)日：1997-07-10
申请号：PCT/GB9601975
申请日：1996-08-13
申请人： ZENECA LTD , BLAKEY DAVID CHARLES , DAVIES DAVID HUW , DOWELL ROBERT IAN , HENNAM JOHN FREDERICK , MARSHAM PETER ROBERT , SLATER ANTHONY MICHAEL , HENNEQUIN LAURENT FRANCOIS AND
发明人： BLAKEY DAVID CHARLES , DAVIES DAVID HUW , DOWELL ROBERT IAN , HENNAM JOHN FREDERICK , MARSHAM PETER ROBERT , SLATER ANTHONY MICHAEL , HENNEQUIN LAURENT FRANCOIS AND
IPC分类号： C12N15/09 , A61K31/00 , A61K31/19 , A61K31/192 , A61K38/46 , A61K39/395 , A61K47/48 , A61P35/00 , C07K16/30 , C07K19/00 , C12N1/21 , C12N9/48 , C12N15/57 , C12R1/19 , A61K
CPC分类号： B82Y5/00 , A61K47/6899 , C12N9/48
摘要： Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumour associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式